From the Department of Pediatrics, Division of Infectious Disease, Medical School of Ege University, Izmir, Turkey.
Department of Pediatrics, Division of Pediatric Hematology & Oncology and Bone Marrow Transplantation, Medical School of Ege University, Izmir, Turkey.
Pediatr Infect Dis J. 2023 May 1;42(5):374-380. doi: 10.1097/INF.0000000000003845. Epub 2023 Feb 2.
The increasing incidence of Stenotrophomonas maltophilia ( S. maltophilia ) infections raises concern because of the high fatality/case ratio. This study aimed to evaluate the risk factors for infection and mortality associated with S. maltophilia bloodstream infections (BSIs) in children and compare them with Pseudomonas aeruginosa BSIs.
All BSIs caused by S. maltophilia (n:73) and P. aeruginosa (n:80) were enrolled in this study between January 2014 and December 2021 at the Medical School of Ege University.
Previous Pediatric Intensive Care Unit (PICU) admission, prior glycopeptide, and carbapenem use were significantly more common in patients with S. maltophilia BSIs ( P = 0.044, P = 0.009, and P = 0.001, respectively) than with P. aeruginosa BSIs. C-reactive protein (CRP) levels were significantly higher in S. maltophilia BSIs ( P = 0.002). Multivariate analysis showed that prior carbapenem use was associated with S. maltophilia BSIs ( P = 0.014, adjusted odds ratio [AOR]: 2.710; 95% confidence interval [CI]: 1.225-5.992). PICU admission because of BSI, prior carbapenem and glycopeptide use, neutropenia, and thrombocytopenia were significantly more common in patients with mortality because of S. maltophilia BSIs ( P < 0.001, P = 0.010, P = 0.007, P = 0.008, P = 0.004, respectively), while only PICU admission because of BSI, and prior glycopeptide use were significant in multivariate analysis (AOR, 19.155; 95% CI: 2.337-157.018; P = 0.006 and AOR, 9.629; 95% CI: 1.053-88.013; P = 0.045, respectively).
Prior carbapenem use is a significant risk factor for developing S. maltophilia BSIs. PICU admission because of BSI and prior glycopeptide use are risk factors associated with the mortality rate in patients with S. maltophilia BSIs. Therefore, S. maltophilia should be considered in patients with these risk factors, and empirical treatment should include antibiotics for S. maltophilia .
嗜麦芽窄食单胞菌(S. maltophilia)感染的发病率不断上升,病死率/发病率高,令人担忧。本研究旨在评估儿童嗜麦芽窄食单胞菌血流感染(BSI)相关感染和死亡的危险因素,并与铜绿假单胞菌 BSI 进行比较。
本研究纳入了 2014 年 1 月至 2021 年 12 月在伊兹密尔艾杰大学医学院因嗜麦芽窄食单胞菌(n=73)和铜绿假单胞菌(n=80)引起的所有 BSI。
与铜绿假单胞菌 BSI 相比,先前入住儿科重症监护病房(PICU)、先前使用糖肽类和碳青霉烯类药物的患者中嗜麦芽窄食单胞菌 BSI 更为常见(P=0.044、P=0.009 和 P=0.001)。嗜麦芽窄食单胞菌 BSI 患者的 C 反应蛋白(CRP)水平显著升高(P=0.002)。多变量分析显示,先前使用碳青霉烯类药物与嗜麦芽窄食单胞菌 BSI 相关(P=0.014,调整后的优势比[OR]:2.710;95%置信区间[CI]:1.225-5.992)。PICU 因 BSI 入住、先前使用碳青霉烯类和糖肽类药物、中性粒细胞减少症和血小板减少症与嗜麦芽窄食单胞菌 BSI 患者死亡显著相关(P<0.001、P=0.010、P=0.007、P=0.008、P=0.004),而仅 PICU 因 BSI 入住和先前使用糖肽类药物在多变量分析中具有统计学意义(OR,19.155;95%CI:2.337-157.018;P=0.006 和 OR,9.629;95%CI:1.053-88.013;P=0.045)。
先前使用碳青霉烯类药物是嗜麦芽窄食单胞菌 BSI 的一个重要危险因素。PICU 因 BSI 入住和先前使用糖肽类药物是嗜麦芽窄食单胞菌 BSI 患者死亡率相关的危险因素。因此,对于具有这些危险因素的患者,应考虑嗜麦芽窄食单胞菌感染,经验性治疗应包括针对嗜麦芽窄食单胞菌的抗生素。